Lantheus Holdings, Aurinia, Whiting, Oasis, and More: What is Going on With These Five Falling Stocks?

Although the Dow Jones is down by just 40 points and the S&P and NASDAQ are off by around half a percent each, shares of five stocks, Lantheus Holdings Inc (NASDAQ:LNTH), Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), Whiting Petroleum Corp (NYSE:WLL), Oasis Petroleum Inc. (NYSE:OAS), and SM Energy Co (NYSE:SM), are deep in the red.

Let’s find out why traders are selling each stock and analyze how hedge funds were positioned among them using the latest 13F filings.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

Lantheus Holdings Inc (NASDAQ:LNTH) is 12% in the red after the company priced a 3 million spot secondary at $12.50 per share. Existing shareholders are the sellers in question and Lantheus itself will not receive any of the proceeds from the sale. Credit Suisse was the underwriter. The number of elite funds with holdings in Lantheus Holdings Inc (NASDAQ:LNTH) rose by 3 quarter-over-quarter to 15 at the end of December. That’s out of the around 742 elite funds in our database.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has fallen by 22% after the company announced the public offering of common shares to be executed by Leerink Partners and Cantor Fitzgerald. According to The Street’s Adam Feuerstein, the company sold 22.3 million shares at around $6.75 a piece, raising $150 million to finance the company’s R&D of the potentially promising drug voclosporin (among other activities). No top funds that we track were long Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) at the end of Q4.

On the next page, we find out why Whiting Petroleum Corp, Oasis Petroleum Inc, and SM Energy Co are deep in the red today.